StemCyte
永笙生技股份有限公司
StemCyte is a Taiwan TWSE-listed biotechnology company; its most advanced asset is REGENECYTE (Phase 3; not yet recruiting, Long COVID; Post-COVID-19 Condition; Post-COVID Syndrome; Post-COVID Condition), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| REGENECYTE | — | Phase 3; not yet recruiting | Long COVID; Post-COVID-19 Condition; Post-COVID Syndrome; Post-COVID Condition | — | 2025-09-23 | Trial registry |
| hUCB | — | Phase 2; not yet recruiting | Acute Ischemic Stroke | — | 2025-02-27 | Trial registry |
| MC001 | — | Phase 2; terminated | Spinal Cord Injuries | Taiwan | 2025-02-28 | Trial registry |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.